HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IRD
Opus Genetics, Inc.
There isn't enough reported data to score IRD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IRD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
IRD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IRD PE Valuation
IRD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IRD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IRD's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.34 |
| Q2 2026 | -$1.33 | +$0.59 |
| Q1 2026 | -$1.31 | +$0.79 |
| Q4 2025 | -$0.80 | +$1.35 |
| Q3 2025 | -$1.88 | -$0.81 |
| Q2 2025 | -$1.92 | -$1.39 |
| Q1 2025 | -$2.10 | -$1.63 |
| Q4 2024 | -$2.15 | -$1.69 |
IRD is still losing money, but far less than before: $1.54 per share over the past year, against $11.55 at its worst in early 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IRD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IRD on profitability, with a higher operating margin.
IRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -63% |
| Q2 2026 | $755K | -74% |
| Q1 2026 | $2.2M | -51% |
| Q4 2025 | $3.9M | -10% |
| Q3 2025 | $3.1M | -20% |
| Q2 2025 | $2.9M | +159% |
| Q1 2025 | $4.4M | +155% |
| Q4 2024 | $4.3M | +154% |
IRD's revenue has slid since its 2022 peak: $1M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1693% | -1423 points |
| Q2 2026 | -2183% | -1874 points |
| Q1 2026 | -666% | -439 points |
| Q4 2025 | -296% | +588 points |
| Q3 2025 | -270% | -63 points |
| Q2 2025 | -309% | +440 points |
| Q1 2025 | -227% | +223 points |
| Q4 2024 | -884% | -563 points |
IRD's operating margin was −1693% last quarter, down 1423 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IRD on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12M | -$1.7M |
| Q1 2026 | -$12.7M | -$3.7M |
| Q4 2025 | -$9.8M | -$2.4M |
| Q3 2025 | -$6.2M | -$1M |
| Q2 2025 | -$10.3M | -$3M |
| Q1 2025 | -$9M | -$3.3M |
| Q4 2024 | -$7.4M | -264% |
| Q3 2024 | -$5.1M | -$2.1M |
IRD has burned cash in almost every quarter: −$41M over the past year, against −$32M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IRD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.6% | -9.5M shares |
| 1 year | +44% | +31.2M shares |
| 3 years | +386% | +80.9M shares |
| 5 years | +832% | +90.9M shares |
| Available history | +10187% | +101M shares |
IRD has 102M diluted shares, up 44% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -2.3x | Net Cash |
IRD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.5 | Neutral |
| Stochastic | 20.4 | Neutral |
IRD's weekly RSI is 50 (neutral) and its Stochastic is 20 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IRD PE vs Healthcare Sector
| Metric | IRD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IRD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 2.2% below |
| 20 week MA | $4.12 | 1.5% below |
| 50 week MA | $3.91 | 3.8% above |
| 100 week MA | $2.58 | 57% above |
| 200 week MA | $2.68 | 51% above |
IRD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.08 | $5.49 | -32% |
| 2021 | $5.49 | $3.81 | -31% |
| 2022 | $3.81 | $2.51 | -34% |
| 2023 | $2.51 | $3.01 | +20% |
| 2024 | $3.01 | $1.18 | -61% |
| 2025 | $1.18 | $2.02 | +71% |
| 2026 YTD | $2.02 | $4.06 | +101% |
IRD has the edge over HIMS on returns for 2026, with the stronger performance.